Dilip Patel, MD
Hematology & Oncology · Greenvale, NYNPI 1649349929
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,010 of the $13,491 with a category attached, or 81.6%. 22 manufacturers reported payments, led by Genentech USA, Inc. at 34.0% of the total. Reporting peaked in 2019 at $12,770 and has fallen 99.4% since, to $78 in 2025.
Across 44 payments — averaging $306.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Dova Pharmaceuticals$4K
- Astellas Pharma US Inc$4K
- Merck$96
- Novartis$93
- Alcon$79
- plus $502 from 16 others
Across 68 payments — averaging $2706.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$75K
- E.r. Squibb & Sons, L.L.C.$69K
- Pharmacyclics LLC, An Abbvie Company$20K
- AbbVie$14K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
What the payments were for
- Consulting fees$11,01082%
- Travel & lodging$1,36410%
- Food & beverage$1,0778%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $4,589 |
| Dova Pharmaceuticals | 2 | $4,365 |
| Astellas Pharma US Inc | 2 | $3,766 |
| Merck | 5 | $96 |
| Novartis | 5 | $93 |
| Alcon | 1 | $79 |
| Menarini Silicon Biosystems, Inc. | 4 | $72 |
| GSK | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Sanofi | 2 | $38 |
| Johnson & Johnson | 1 | $30 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $24 |
| Gilead | 1 | $23 |
| Tempus AI, Inc | 1 | $20 |
| Seagen Inc. | 1 | $20 |
| Global Blood Therapeutics, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,491 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $9,339 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Greenvale
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.